QC
ZNTL icon

Quadrature Capital’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Quadrature Capital’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$182K Buy
37,613
+4,281
+13% +$17.1K ﹤0.01% 1374
2026
Q1 		$78K Sell
33,332
-104,236
-76% -$269K ﹤0.01% 1255
2025
Q4 		$186K Buy
137,568
+76,917
+127% +$112K ﹤0.01% 992
2025
Q3 		$92.2K Buy
60,651
+8,195
+16% +$12.3K ﹤0.01% 885
2025
Q2 		$60.6K Buy
+52,456
New +$69.2K ﹤0.01% 931

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Quadrature Capital's ZNTL Position: Q2 2026 in Review

Quadrature Capital increased its Zentalis Pharmaceuticals (ZNTL) stake by 13% in Q2 2026, buying an estimated $17.1K and bringing the position to 37,613 shares worth $182K. The position accounts for ﹤0.01% of the portfolio, ranked #1374.

Quadrature Capital first reported a position in ZNTL in Q2 2025 and has held it in 5 quarters since. The position peaked at $186K in Q4 2025. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Quadrature Capital held 37,613 shares of Zentalis Pharmaceuticals worth $182K as of Q2 2026.
  • Quadrature Capital bought 4,281 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $17.1K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1374 holding.
  • Quadrature Capital first reported a position in Zentalis Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Quadrature Capital's Zentalis Pharmaceuticals position peaked at $186K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.